Cargando…

Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States

Background. Nifurtimox is 1 of only 2 medications available for treating Chagas disease (CD) and currently the only drug available in the United States, but its safety and tolerance have not been extensively studied. This is the first study to evaluate tolerance of nifurtimox in US patients with CD....

Descripción completa

Detalles Bibliográficos
Autores principales:	Forsyth, Colin J., Hernandez, Salvador, Olmedo, Wilman, Abuhamidah, Adieb, Traina, Mahmoud I., Sanchez, Daniel R., Soverow, Jonathan, Meymandi, Sheba K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Articles and Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036918/ https://www.ncbi.nlm.nih.gov/pubmed/27432838 http://dx.doi.org/10.1093/cid/ciw477

Ejemplares similares

Prevalence of Chagas Disease in a U.S. Population of Latin American Immigrants with Conduction Abnormalities on Electrocardiogram
por: Traina, Mahmoud I., et al.
Publicado: (2017)

Prevalence of Chagas Disease in the Latin American–born Population of Los Angeles
por: Meymandi, Sheba K., et al.
Publicado: (2017)

Progression of Baseline Electrocardiogram Abnormalities in Chagas Patients Undergoing Antitrypanosomal Treatment
por: Soverow, Jonathan, et al.
Publicado: (2019)

Treatment of Chagas Disease in the United States
por: Meymandi, Sheba, et al.
Publicado: (2018)

Repolarization Parameters Are Associated With Mortality In Chagas Disease Patients In The United States
por: Bradfield, Jason, et al.
Publicado: (2014)

Prevalence of Chagas Disease Among Family Members of Previously Diagnosed Patients in Los Angeles, California
por: Hernandez, Salvador, et al.
Publicado: (2019)

Proposed multidimensional framework for understanding Chagas disease healthcare barriers in the United States
por: Forsyth, Colin, et al.
Publicado: (2019)

Safety Profile of Nifurtimox and Treatment Interruption for Chronic Chagas Disease in Colombian Adults
por: Olivera, Mario Javier, et al.
Publicado: (2015)

“It’s Like a Phantom Disease”: Patient Perspectives on Access to Treatment for Chagas Disease in the United States
por: Forsyth, Colin J., et al.
Publicado: (2018)

Neglected Parasitic Infections in the United States: Chagas Disease
por: Montgomery, Susan P., et al.
Publicado: (2014)

Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas’ disease
por: Jackson, Yves, et al.
Publicado: (2020)

Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
por: Rolon, Miriam, et al.
Publicado: (2022)

Cardiac inflammation and ventricular tachycardia in Chagas disease
por: Shapiro, Hilary, et al.
Publicado: (2017)

Response To Letter To The Editor Regarding Article "Repolarization Parameters Are Associated With Mortality In Chagas Disease Patients In The United States"
por: Bradfield, J, et al.
Publicado: (2014)

Recommendations for Screening and Diagnosis of Chagas Disease in the United States
por: Forsyth, Colin J, et al.
Publicado: (2021)

1210. Recommendations for Screening and Diagnosis of Chagas Disease in the United States
por: Forsyth, Colin, et al.
Publicado: (2021)

Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatment
por: Santamaria, Cynthia, et al.
Publicado: (2014)

Detection of Trypanosoma cruzi by PCR in adults with chronic Chagas disease treated with nifurtimox
por: Vergara, Camilo, et al.
Publicado: (2019)

Autochthonous Transmission of Trypanosoma Cruzi in Southern California
por: Hernandez, Salvador, et al.
Publicado: (2016)

Serological and parasitological response in chronic Chagas patients 3 years after nifurtimox treatment
por: Jackson, Yves, et al.
Publicado: (2013)

Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease
por: Moroni, Samanta, et al.
Publicado: (2019)

Serological response to nifurtimox in adult patients with chronic Chagas disease: An observational comparative study in Argentina
por: Vizcaya, David, et al.
Publicado: (2021)

Biopharmaceutical Characteristics of Nifurtimox Tablets for Age‐ and Body Weight‐Adjusted Dosing in Patients With Chagas Disease
por: Stass, Heino, et al.
Publicado: (2020)

Effectiveness of Nifurtimox in the Treatment of Chagas Disease: a Long-Term Retrospective Cohort Study in Children and Adults
por: Falk, N., et al.
Publicado: (2022)

Recognition and screening for Chagas disease in the USA
por: Marcus, Rachel, et al.
Publicado: (2021)

COVID-19: Implications for People with Chagas Disease
por: Zaidel, Ezequiel José, et al.
Publicado: (2020)

Critical analysis of Chagas disease treatment in different countries
por: Mendes, Fernanda de Souza Nogueira Sardinha, et al.
Publicado: (2022)

Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE)
por: Altcheh, Jaime, et al.
Publicado: (2023)

Nifurtimox Inhibits the Progression of Neuroblastoma in vivo
por: Kong, Eryan, et al.
Publicado: (2019)

An Unfolding Tragedy of Chagas Disease in North America
por: Hotez, Peter J., et al.
Publicado: (2013)

Quantification of Immunoglobulin G against Trypanosoma cruzi in Individuals with Chronic Chagas Disease Treated with Nifurtimox and Evaluated in Prolonged Follow-Up
por: Muñoz, Gabriela, et al.
Publicado: (2019)

Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease — United States, 2001–2021
por: Abbott, Andrew, et al.
Publicado: (2022)

Follow-up of an Asymptomatic Chagas Disease Population of Children after Treatment with Nifurtimox (Lampit) in a Sylvatic Endemic Transmission Area of Colombia
por: Bianchi, Fiorella, et al.
Publicado: (2015)

Structural and Mechanistic Investigation of the Unusual Metabolism of Nifurtimox
por: Lang, Dieter, et al.
Publicado: (2022)

Development of Diagnostics for Chagas Disease: Where Should We Put Our Limited Resources?
por: Picado, Albert, et al.
Publicado: (2017)

Chagas disease among pregnant Latin American women in the United Kingdom: time for action
por: Fernandez Turienzo, Cristina, et al.
Publicado: (2017)

Correction to “Structural and Mechanistic Investigation of the Unusual Metabolism of Nifurtimox”
por: Lang, Dieter, et al.
Publicado: (2023)

ELISA F29 –A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment
por: Rivero, Rocio, et al.
Publicado: (2023)

Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO)
por: Altcheh, Jaime, et al.
Publicado: (2021)

"I Cannot Be Worried": Living with Chagas Disease in Tropical Bolivia
por: Forsyth, Colin J.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jp6s6aomv2d6g1pvp3o3j84d40